Pages that link to "Q61971038"
Jump to navigation
Jump to search
The following pages link to Platelets Take Up the Monoclonal Antibody Bevacizumab (Q61971038):
Displaying 38 items.
- Recent advances of novel targeted therapy in non-small cell lung cancer (Q21092930) (← links)
- A systems biology view of blood vessel growth and remodelling (Q27003945) (← links)
- Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles (Q28538098) (← links)
- A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. (Q30433214) (← links)
- A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap (Q30439884) (← links)
- A compartment model of VEGF distribution in blood, healthy and diseased tissues. (Q30441056) (← links)
- Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress (Q30577008) (← links)
- Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial (Q33439523) (← links)
- Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies (Q34079689) (← links)
- Selective sorting of alpha-granule proteins (Q34415721) (← links)
- Biomarkers of response and resistance to antiangiogenic therapy (Q34673567) (← links)
- Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review (Q35009777) (← links)
- A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients (Q35193385) (← links)
- Bevacizumab (Q35584234) (← links)
- Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. (Q35703000) (← links)
- Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation (Q36299062) (← links)
- Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions (Q36901312) (← links)
- The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer (Q37141960) (← links)
- Ectopic platelet-delivered factor (F) VIII for the treatment of Hemophilia A: Plasma and platelet FVIII, is it all the same? (Q37366619) (← links)
- Contribution of platelets to tumour metastasis. (Q37831798) (← links)
- Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology (Q38128286) (← links)
- A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. (Q38749030) (← links)
- Vascular endothelial growth factor A (VEGF-A) decreases expression and secretion of pleiotrophin in a VEGF receptor-independent manner. (Q38790301) (← links)
- Targeting Platelets for the Treatment of Cancer. (Q39454244) (← links)
- A Rupture of a Lung Metastatic Lesion of Colon Cancer, Leading to Pneumothorax Caused by Bevacizumab (Q41939405) (← links)
- VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. (Q42039078) (← links)
- Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models (Q42132001) (← links)
- Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression (Q47668446) (← links)
- Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians (Q50214698) (← links)
- Angiogenesis in spontaneous tumors and implications for comparative tumor biology. (Q51301228) (← links)
- Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. (Q51804140) (← links)
- The Platelet Lifeline to Cancer: Challenges and Opportunities. (Q52719266) (← links)
- Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab. (Q54121709) (← links)
- Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates (Q62566471) (← links)
- (Q64449238) (redirect page) (← links)
- [Subretinal co-application of rtPA and bevacizumab for exudative AMD with submacular hemorrhage. Compatibility and clinical long-term results] (Q84509885) (← links)
- A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys (Q88006648) (← links)
- Tyrosine Kinase Inhibitor-Induced Hypertension (Q89183946) (← links)